Weill Cornell Medicine researchers received a $1 million PCF Challenge Award to develop an AI model for early detection of treatment-resistant prostate cancer subtypes.
Key Details
- 1Dr. Ekta Khurana leads the project, collaborating with Memorial Sloan Kettering Cancer Center.
- 2The team received a $1 million, two-year Prostate Cancer Foundation Challenge Award.
- 3Research focuses on AI models trained on pathology slides, gene activity, and treatment outcomes.
- 4Project aims to identify patients with tumors likely to develop resistance early so they can be matched to appropriate trials.
- 5Validation of the developed AI model in clinical trials is planned for a follow-on project.
Why It Matters
Developing AI tools to distinguish treatment-resistant tumor subtypes could significantly improve personalized care and trial selection for prostate cancer, addressing a pressing clinical need. Integration of pathology, genomics, and AI in this way is at the forefront of imaging-based precision medicine.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
Duke Receives $25M to Lead National Trustworthy AI Hub for Dementia and Aging
Duke University has launched a $25 million national center to make AI for aging and dementia clinically robust and trustworthy.